AstraZeneca Closer To Filing Anifrolumab For Lupus
Success After Switching Endpoints In TULIP 2
Having recovered from a late-stage fail last year, AstraZeneca has fleshed out results from a positive second Phase III trial of anifrolumab which it hopes will be the second new lupus treatment to hit the market in 60 years.
